Amgen Announces New LUMAKRAS Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021

Amgen today announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy of LUMAKRAS™ the first and only approved KRAS G12C inhibitor, in more than 10 different investigational combination regimens for the treatment of patients with KRAS G12C-mutated cancers. Results from two arms of the study — LUMAKRAS with ...

Related Keywords

United Arab Emirates ,Australia ,Taiwan ,Japan ,Hong Kong ,Brazil ,Colombia ,Canada ,Umeki ,Ankara ,Turkey ,Mexico ,Puerto Rico ,Thailand ,Israel ,Singapore ,South Korea ,Switzerland ,Megan Fox ,Trish Rowland ,Davidm Reese ,Kyowa Kirin Co Ltd ,Amgen ,Drug Administration ,Beigene Ltd ,Virtual International Conference On Molecular ,Exchange Commission ,Therapeutics Inc ,European Union ,Drugging Difficult Target ,International Conference ,Molecular Targets ,Cancer Therapeutics ,Great Britain ,Real Time Oncology Review ,Marketing Authorization Applications ,Important Safety Information ,Lung Disease ,Prescribing Information ,Amgen Oncology ,Five Prime Therapeutics ,Thousand Oaks ,Englj Med ,